Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
Current price $0.0001
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Oct 18, 23 | TD Cowen | downgrade | Outperform | Market Perform |
| Jul 26, 23 | Morgan Stanley | maintain | Equal Weight | Equal Weight |
| Feb 15, 23 | Morgan Stanley | maintain | Equal Weight | Equal Weight |
| Nov 16, 22 | Chardan Capital | downgrade | Buy | Neutral |
| Sep 9, 22 | Morgan Stanley | maintain | Equal Weight | Equal Weight |
| Aug 24, 22 | Morgan Stanley | maintain | Equal Weight | Equal Weight |
| Aug 15, 22 | Chardan Capital | maintain | Buy | Buy |
| Nov 2, 21 | JMP Securities | maintain | Market Outperform | Market Outperform |
| Nov 1, 21 | Chardan Capital | upgrade | Neutral | Buy |
1252 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-10-21
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 38.17 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 66.67 | Oscillator | Neutral |
| Williams %R (14) | -100.00 | Oscillator | Buy |
| MACD (12, 26, 9) | 0.00 (Hist -0.00) | Oscillator | Sell |
| Average Directional Index (14) | 17.34 (+DI 38.3 / -DI 61.7) | Trend | Neutral |
| EMA 20 | 0.00 | MA | Strong Sell |
| SMA 20 | 0.00 | MA | Strong Sell |
| EMA 50 | 0.00 | MA | Strong Sell |
| SMA 50 | 0.00 | MA | Strong Sell |
| SMA 200 | 0.00 | MA | Strong Sell |
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Nov 7, 23 | Bodmer Mark | officer: CSO, President of R&D | M-Exempt | 6,625 | — |
| Nov 8, 23 | Bodmer Mark | officer: CSO, President of R&D | S-Sale | 3,163 @ $0.33 | $1.04K |
| Nov 7, 23 | Bodmer Mark | officer: CSO, President of R&D | M-Exempt | 6,625 | — |
| Nov 7, 23 | Mchale Duncan | officer: Chief Medical Officer | M-Exempt | 6,500 | — |
| Nov 8, 23 | Mchale Duncan | officer: Chief Medical Officer | S-Sale | 3,103 @ $0.33 | $1.02K |
| Nov 7, 23 | Mchale Duncan | officer: Chief Medical Officer | M-Exempt | 6,500 | — |
| Nov 7, 23 | Gill Simba | director, officer: President & CEO | M-Exempt | 1,172 | — |
| Nov 8, 23 | Gill Simba | director, officer: President & CEO | S-Sale | 172 @ $0.33 | $57 |
TTM vs. 5-year historical average (annual ratios)
| Metric | EVLO | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -0.0x | -3.2x · sector 20.7x | Discount |
| Forward P/E (FY23E) | -0.0x | EPS est. -2.26 | Elevated |
| Price / Book | -0.0x | 5.8x | Discount |
| Price / Sales | — | — | n/a |
| EV / EBITDA | -0.0x | -2.5x | Discount |
| Return on equity | -6232.8% | — | Weak |
| Gross margin | 0.0% | 0.0% | n/a |
| Debt / Equity | -10.24 | -0.40 | Conservative |
| Piotroski / Altman Z | 3/9 | Z -53.28 | Distress |
Discounted cash flow model
SEC EDGAR filings · last 12 months
Proxy statement (DEF 14A) disclosures
Stock news · updated daily
Reported EPS vs. consensus estimate